Skip to main content
TipRanks
Go Ultimate75% OFF

Standard Chemical & Pharmaceutical Co. Ltd. (1720) AI Stock Analysis

TW:1720

Standard Chemical & Pharmaceutical Co. Ltd.

(TWSE:1720)

Select Model
Rating:65Neutral
Price Target:TWD 59.00â–²(6.69% Upside)
Action:downgraded
Date:11/18/26

The company's financial foundation is a significant strength, characterized by a debt-light balance sheet and superb free cash flow generation. However, this is offset by weak technical momentum, with the stock trading below key moving averages and showing bearish signals. The low P/E ratio and solid dividend yield provide a valuation cushion, making the stock fundamentally attractive but currently out of favor in the market.

Positive Factors
Durable ProfitabilityStrong operating, EBITDA, and net margins indicate that the company converts revenue into profit efficiently. This profitability provides internal funding for product development and commercialization while offering resilience if sales growth moderates over the next several quarters.
Negative Factors
Volatile Revenue GrowthRevenue expansion is a fundamental strength, but the unusually high recent growth rate and uneven prior-year pattern indicate an unstable growth profile. Volatility makes future planning less predictable and increases the risk that reported sales momentum will not persist consistently.

Standard Chemical & Pharmaceutical Co. Ltd. (1720) vs. SPDR S&P 500 ETF (SPY)

-10%-5%0%5%10%15%20%25%TW:1720-0.30%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 10.91B
Dividend Yield
3.62%
Average Volume (3M)
224.76K
Price to Earnings (P/E)
10.8
Beta (1Y)
0.11
Revenue Growth
4.62%
EPS Growth
9.56%
Country
TW
Employees
1,130
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Standard Chemical & Pharmaceutical Co. Ltd. Business Overview & Revenue Model

Company Description

Standard Chem & Pharm Co. Ltd. (SCP) is a Taiwanese enterprise specializing in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products, nutritional supplements, and Active Pharmaceutical Ingredients (APIs)...

Standard Chemical & Pharmaceutical Co. Ltd. Financial Statement Overview

Summary

Strong financial health driven by excellent cash flow (Score 85) and a robust, deleveraging balance sheet (Score 78). Modest but stable revenue growth and improving profitability support a solid, though not exceptional, overall financial profile.

Income Statement

72Positive

Balance Sheet

78Positive

Cash Flow

85Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue7.23B7.02B6.79B6.24B5.85B4.60B
Gross Profit3.13B2.91B2.99B2.73B2.49B2.07B
EBITDA1.91B1.80B2.06B1.61B1.66B1.25B
Net Income1.00B927.66M880.50M834.89M1.15B706.73M
Balance Sheet
Total Assets12.12B11.80B11.18B11.19B10.97B10.10B
Cash, Cash Equivalents and Short-Term Investments2.16B2.39B1.81B2.28B2.60B2.99B
Total Debt970.30M1.13B921.19M1.33B2.25B1.97B
Total Liabilities2.44B2.51B2.20B3.05B3.53B3.30B
Stockholders Equity6.45B6.12B5.91B5.30B4.75B4.34B
Cash Flow
Free Cash Flow1.23B1.38B1.10B710.83M30.29M609.12M
Operating Cash Flow1.72B1.87B1.69B1.34B1.23B827.03M
Investing Cash Flow-822.93M-1.31B-771.69M-485.50M-1.08B819.12M
Financing Cash Flow-722.30M-309.71M-1.44B-1.08B-465.44M-117.54M

Standard Chemical & Pharmaceutical Co. Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price55.30

Price Trends

50DMA56.24Negative
100DMA56.33Negative
200DMA55.59Negative

Market Momentum

MACD-0.40Positive
RSI41.59Neutral
STOCH40.44Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:1720, the sentiment is Negative. The current price of 55.30 is below the 20-day moving average (MA) of 56.02, below the 50-day MA of 56.24, and below the 200-day MA of 55.59, indicating a bearish trend. The MACD of -0.40 indicates Positive momentum. The RSI at 41.59 is Neutral, neither overbought nor oversold. The STOCH value of 40.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TW:1720.

Standard Chemical & Pharmaceutical Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:1720 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:3218TW:321873OutperformTWD 10.42B9.71―6.33%4.80%8.73%
TW:1720TW:172065NeutralTWD 10.87B10.84―3.62%4.62%9.56%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:6535TW:653552NeutralTWD 14.66B-33.97――-24.84%9.09%
TW:6576TW:657642NeutralTWD 11.01B-1165.00――6.41%―
TW:6945TW:694540UnderperformTWD 11.70B-34.27――――

* General Sector Average

Performance Comparison

-50%0%50%100%TW:1720TW:3218TW:6467TW:6535TW:6576TW:6945Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:1720 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:1720Standard Chemical & Pharmaceutical Co. Ltd.55.30-0.17-0.30%
TW:3218Universal Vision Biotechnology Co., Ltd.122.50-18.16-12.91%
TW:6467TAHO Pharmaceuticals Ltd224.5052.0030.14%
TW:6535LUMOSA THERAPEUTICS CO LTD83.30-98.70-54.23%
TW:6576Foresee Pharmaceuticals Co., Ltd.69.90-5.90-7.78%
TW:6945AP Biosciences, Inc.120.0011.5010.60%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026